AstraZeneca records 50% share of gross profits on sales of Beyfortus in major markets outside the United States and 25% of ...

Beyfortus made almost $600 million in its first full year on the market in 2023, even though it was held back by manufacturing capacity constraints, and AZ and Sanofi are predicting it will cross ...

Aug 17, 2024 18:48 Sanofi Gets CDSCO Nod for Beyfortus in India - Prevention of RSV Sanofi India receives marketing authorization for Beyfortus, a treatment for preventing Respiratory Syncytial Virus ...

Pregnant mums and newborns will receive free vaccinations against respiratory syncytial virus (RSV) under the federal ...

Sanofi gets rated buy today, agreeing with bullish ratings from the Wall Street and SA analysts' consensus. With a diverse ...

A treatment of acute myeloid leukemia being developed by Sanofi (SNY) US Services was granted FDA orphan designation, according to a post to the agency’s website. Published first on TheFly – the ...

Sanofi (SNY) has released an update. Sanofi’s Dupixent has received EU approval as the first treatment for children aged one to 11 with ...

Sanofi India Q3 Results Live : Sanofi India announced its Q3 results on November 7, 2024, revealing a significant decline in both revenue and profit. The company reported a topline decrease of 26. ...

The European Medicines Agency (EMA) approved Sanofi/Regeneron’s Dupixent (dupilumab) to treat eosinophilic esophagitis (EoE) in children as young as one. The approval extends the use of Dupixent ...

Shortly after Amgen unveiled its $1.9 billion alliance with Generate Biomedicines aimed initially at five drug molecules, Sanofi has announced a big expansion of its longstanding partnership with ...

The booth of France's largest healthcare company, Sanofi, showcases the innovative treatment Tzield, the world's first and only disease modifying therapy to delay the onset of type 1 diabetes and ...